The latest oncology coverage from Hawaii Medical Journal.
A recent phase III randomized controlled trial published in the New England Journal of Medicine demonstrated significant clinical benefit for trastuzumab deruxtecan in patients with residual HER2-positive early breast cancer following neoadjuvant therapy. The findings support adjuvant antibody-drug conjugate therapy in this high-risk population.
A comprehensive analysis of tecovirimat's clinical efficacy in mpox treatment demonstrates significant reduction in lesion resolution time and viral shedding duration. The findings establish tecovirimat as a viable therapeutic option for severe mpox infections requiring antiviral intervention.
A phase III randomized controlled trial demonstrates statistically significant improvement in disease-free survival with adjuvant durvalumab plus tremelimumab in resectable renal cell carcinoma. The combination regimen represents a potential paradigm shift in postoperative management of high-risk RCC patients.
A phase I dose-escalation study of rezatapopt demonstrated preliminary antitumor activity in patients with TP53 Y220C-mutated solid tumors, representing the first clinical validation of mutation-specific p53 reactivation therapy.